Antibiotic LA 7017

Base Information

• Chemical Name: Antibiotic LA 7017
• CAS No.: 18378-89-7
• Molecular Formula: C₅₂H₇₆O₂₄
• Molecular Weight: 1085.16
• Hs Code.: 29419090
• European Community (EC) Number: 634-048-4
• Wikipedia: Plicamycin
• Wikidata: Q104956352
• NCI Thesaurus Code: C658
• Metabolomics Workbench ID: 125241
• ChEMBL ID: CHEMBL1881779
• Mol file: 18378-89-7.mol

Synonyms:mithramycin A;Aureolic Acid;Mithramycin;Mitramycin;Plicamycin

Chemical Property of Antibiotic LA 7017

Chemical Property:

• Appearance/Colour: yellow powder
• Vapor Pressure: 0mmHg at 25°C
• Melting Point: 180-183 °C
• Refractive Index: 1.639
• Boiling Point: 1169.8 °C at 760 mmHg
• PKA: 4.54±0.60(Predicted)
• Flash Point: 327.4 °C
• PSA: 358.20000
• Density: 1.48 g/cm³
• LogP: -0.24930
• Storage Temp.: 2-8°C
• Solubility.: Soluble in DMSO (up to 20 mg/ml) or in Ethanol (up to 10 mg/ml)
• XLogP3: 0.6
• Hydrogen Bond Donor Count: 11
• Hydrogen Bond Acceptor Count: 24
• Rotatable Bond Count: 15
• Exact Mass: 1084.47265329
• Heavy Atom Count: 76
• Complexity: 1940

Purity/Quality:

98%,99%, ^*data from raw suppliers

Mithramycin ^*data from reagent suppliers

Safty Information:

• Pictogram(s): Xn, T+
• Hazard Codes: Xn,T+
• Statements: 22-26/27/28
• Safety Statements: 45-38-36/37/39-28A-22

MSDS Files:

SDS file from LookChem

Total 1 MSDS from other Authors

Useful:

• Drug Classes: Antineoplastic Agents
• Canonical SMILES: CC1C(C(CC(O1)OC2CC(OC(C2O)C)OC3=CC4=CC5=C(C(=O)C(C(C5)C(C(=O)C(C(C)O)O)OC)OC6CC(C(C(O6)C)O)OC7CC(C(C(O7)C)O)OC8CC(C(C(O8)C)O)(C)O)C(=C4C(=C3C)O)O)O)O
• Description: Mithramycin is an antineoplastic antibiotic produced by Streptomyces plicatus. It is well known as the aureolic acid antitumor antibiotic that inhibits both cancer growth and bone resorption by cross-linking GC-rich DNA, thus blocking binding of Sp-family transcription factors to gene regulatory elements. Transcription of c-Src, a gene implicated in many human cancers and required for osteoclast-dependent bone resorption, is regulated by the binding of Sp factors to specific elements in its promoter. Therefore, this gene represents an important anticancer target and a potential lead target through which mithramycin displays action against osteoclastic bone resorption via an unknown mechanism. Hazards of handling this drug by the health-care personnel arise from a combination of factors: (1) its inherent toxicity and (2) the extent to which workers are exposed to the drug in the course of carrying out their duties. This exposure may be through inadvertent ingestion of the drug on foodstuffs (e.g., workers’ lunches), inhalation of drug dusts or droplets, or direct skin contact. Mithramycin has been used to decrease bone resorption in patients with humoral hypercalcemia and Paget’s disease.
• Uses: Transcription inhibitor Mithramycin was the first of the aureolic acid class of antitumour antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts. Mithramycin A was the first of the aureolic acid class of antitumor antibiotics, isolated from Streptomyces. Mithramycin inhibits transcription and protein synthesis by non-covalent binding with G-C-rich duplex DNA in the presence of magnesium and zinc ions. Mithramycin also induces differentiation of leukemic cells accompanied by an early decrease in c-myc expression, and selectively inhibits collagen-1 gene expression in human fibroblasts.
• Indications: Plicamycin (mithramycin, Mithracin) is one of the chromomycin group of antibiotics produced by Streptomyces tanashiensis. Plicamycin binds to DNA and inhibits transcription. It also inhibits resorption of bone by osteoblasts, thus lowering serum calcium levels.Very little is known about its distribution, metabolism, and excretion. Because of its severe toxicity, plicamycin has limited clinical utility.The major indication for plicamycin therapy is in the treatment of life-threatening hypercalcemia associated with malignancy. Plicamycin also can be used in the palliative therapy of metastatic testicular carcinoma when all other known active drugs have failed.

Technology Process of Antibiotic LA 7017

There total 1 articles about Antibiotic LA 7017 which guide to synthetic route it. The literature collected by LookChem mainly comes from the sharing of users and the free literature resources found by Internet computing technology. We keep the original model of the professional version of literature to make it easier and faster for users to retrieve and use. At the same time, we analyze and calculate the most feasible synthesis route with the highest yield for your reference as below:

synthetic route:

Reference yield:

→ mithramycin (18378-89-7,97666-60-9)

Guidance literature:

Refernces

• 1、 -. "Anti-Claudin 3 Monoclonal Antibody and Treatment and Diagnosis of Cancer Using the Same". . . Retrieved 2010/05/13.
• 2、 -. "Medicines for treating tumoral pathologies containing the ro5-4864 compound and an apoptosis-inducing agent". . . Retrieved 2008/06/13.